Promising combo trial for lymphoma halted early
Disease control
Terminated
This early-stage trial tested a combination of two immune-boosting drugs—pembrolizumab (Keytruda) and CMP-001—in 14 adults with lymphomas that had come back or stopped responding to treatment. The goal was to find a safe dose that could shrink tumors. However, the study was termi…
Phase: PHASE1, PHASE2 • Sponsor: Umar Farooq • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC